

Peripheral modulation of the endocannabinoid system in metabolic disease

Nirajan Shrestha¹, James S.M. Cuffe¹, Dana S. Hutchinson², John P. Headrick¹, Anthony V.

Perkins¹, Andrew J. McAinch^{3,4} and Deanne H. Hryciw^{3,5,*}

¹School of Medical Science, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia

²Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia

³Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia

⁴Australian Institute of Musculoskeletal Science (AIMSS), College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia

⁵School of Natural Science, Menzies Health Institute Queensland, Griffith University, Nathan, QLD, Australia

*Corresponding author: Hryciw, D.H. (d.skelly@griffith.edu.au).

Highlights:

- The endocannabinoid system (ECS) is dysregulated in obesity-associated diseases
- CB₁ antagonism is a potential therapeutic target for the treatment of obesity
- CB₁ antagonists have the potential for eliciting severe psychiatric side effects
- Antagonists of CB₁ that do not cross the blood–brain barrier are in development
- Peripherally restricted CB₁ antagonists are novel therapeutic targets for obesity

Teaser: This Keynote review discusses the peripheral modulation of the ECS in liver, adipose tissue, heart, skeletal muscle, gastrointestinal tract, pancreas, kidney and the immuno-inflammatory system.

Dysfunction of the endocannabinoid system (ECS) has been identified in metabolic disease. Cannabinoid receptor 1 (CB₁) is abundantly expressed in the brain but also expressed in the periphery. Cannabinoid receptor 2 (CB₂) is more abundant in the periphery, including the immune cells. In obesity, global antagonism of overexpressed CB₁ reduces bodyweight but leads to centrally mediated adverse psychological outcomes. Emerging research in isolated cultured cells or tissues has demonstrated that targeting the endocannabinoid system in the periphery alleviates the pathologies associated with metabolic disease. Further, peripheral specific cannabinoid ligands can reverse aspects of the metabolic phenotype. This Keynote review will focus on current research on the functionality of peripheral modulation of the ECS for the treatment of obesity.

Keywords: Cannabinoid receptor; endocannabinoid system; peripherally restricted cannabinoid antagonist; obesity.

Introduction

The prevalence of metabolic disorders has increased exponentially worldwide. Metabolic diseases are the result of excessive systemic adiposity (obesity), insulin resistance, type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Investigation of potential therapeutic treatments for metabolic disease has focused, in part, on targets that are modulated by fatty acids or their derivatives. The endocannabinoid system (ECS) is a lipid-derived signaling system [1] that can modulate energy expenditure. The most extensively characterized of the cannabinoid (CB) receptors are CB₁ and CB₂ [1]. Endogenous agonists for these receptors are synthesized on demand and degraded via cellular uptake and enzymatic hydrolysis [2] (Figure 1). Herein, we discuss the recent advances in research regarding the roles of CB₁ and CB₂ in metabolic disease, and how pharmaceutical agents that act as ligands for these receptors can be used in the prevention and treatment of metabolic diseases through specific modulation in the periphery.

CB₁ and CB₂

The ECS comprises several ligands and two main receptors: CB₁ and CB₂. CB₁ are the most abundantly expressed G-protein-coupled receptor (GPCR) in the central nervous system (CNS) [3], with elevated expression in the hippocampus, cortex, cerebellum and basal ganglia. The main physiological function of CB₁ is modulation of neurotransmission. CB₁ has also been localized in the periphery, with expression in the dorsal root ganglion, myelinated nerve fiber bundles in the skin, macrophages, mast cells, the gastrointestinal system (predominantly in the cholinergic neurons of the myenteric), spleen, tonsils, leukocytes, skeletal muscle and renal cells [4]. By contrast, CB₂ is predominately expressed in immune cells, particularly in the spleen, thymus and circulating immune cells [5]. In immune cells, CB₂ mainly regulates

immune responses and inflammation. In addition, CB₂ is also expressed in skeletal, cardiovascular and renal systems. CB₂ is also localized with low levels of expression in the CNS, mainly in the cell bodies and dendrites of the central neurons [6]. Furthermore, CB₁ and CB₂ are also expressed in osteoblasts and osteoclasts, where they stimulate bone formation and remodeling [7,8].

In addition to CB₁ and CB₂, several other proteins have been suggested to be CB receptors based on their ability to be activated by endocannabinoids or other CB ligands. These include GPR18 [9], GPR55 and GPR119 [10]. These receptors display little similarity to CB₁ and CB₂ but can be activated by *N*-arachidonoylglycine, lysophosphatidylinositol and *N*-oleoylethanolamide, respectively. However, there is no evidence that they can be activated by these ligands *in vivo*. As such, the International Union of Basic and Clinical Pharmacology Committee (IUPHAR) on Receptor Nomenclature and Drug Classification has not classified them as CB receptors and they have retained their orphan status. There is some evidence, however, that these receptors form heterodimers with CB receptors. GPR55 heterodimerizes with CB₁ [11,12] and CB₂ [13], which could have functional significance in tissues where both receptors are co-expressed. Together with other GPCRs, endocannabinoids or other CB ligands can activate transient receptor potential (TRP) channels [14], and potentiate glycine receptors [15].

CB receptor ligands

CB receptors are activated by two endogenous ligands [*N*-arachidonylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG)], plant-derived cannabinoids [including tetrahydrocannabinol (THC)] and a range of synthetic ligands. Based on chemical structures, CB receptor agonists are subclassified into four groups. Classical CBs consist of tricyclic

dibenzopyran derivatives that are either naturally extracted compounds of cannabis or synthetic analogs of these compounds. The most widely studied naturally isolated CBs are delta-9-tetrahydrocannabinol (Δ^9 -THC) and Δ^8 -THC [16,17]. Δ^9 -THC has a similar affinity to AEA for CB₁; however, it displays lower efficacy than AEA at CB₂ than at CB₁ [18]. The nonclassical CBs contain bicyclic and tricyclic analogs of Δ^9 -THC, including 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol (CP55,940), an agonist with similar affinities for both CB receptors [19]. The third group of CB receptor agonists are the aminoalkylindole cannabinoids, including (*R*)-(+)-[2,3-dihydro-5-methyl-3[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate salt (WIN 55212). WIN 55212 has a high affinity for both receptor subtypes, with a slightly greater affinity for CB₁ [17,20]. The fourth group, eicosanoid CBs include AEA [21] and 2-AG [22]. Among all eicosanoid CBs, 2-AG exhibits the highest intrinsic activities at CB₁ and CB₂. AEA has a lower affinity for CB receptors and acts as a partial agonist, exhibiting mixed agonist–antagonist properties at CB₁ and CB₂.

CB receptor signaling

CB receptors predominately couple to the inhibitory Gi/o G proteins, which inhibit adenylate cyclase activity and subsequently decrease intracellular cyclic AMP levels. However, as is common with many other GPCRs, pleotropic coupling of CB receptors to other effector proteins has been reported. These include activation of Gq and Gs proteins, β -arrestin recruitment, inhibition of voltage-gated calcium channels, stimulation of inwardly rectifying potassium currents and activation of mitogen-activated protein kinase (MAPK) signaling pathways, reviewed in [23]. Because CB receptors can couple or signal to multiple effector proteins, the likelihood of biased signaling to occur is increased. Biased signaling can be

defined as ligand-dependent selectivity for specific signal transduction pathways following activation of the same receptor. It is thought to occur when different ligands bind to a receptor to cause different receptor conformations, enabling the receptor to preferentially signal to one pathway over another. Biased signaling at CB₁ and CB₂ has been reported (i.e., [24,25] for CB₁ and [26,27] for CB₂). The significance of biased signaling is attractive, in that theoretically one could design a drug with fewer side effects. However, further work is warranted in the CB receptor field to delineate those coupled signaling pathways that are beneficial or detrimental following CB activation.

Central dysfunction of the ECS in metabolic disease

The ECS is well recognized to have a vital role in the regulation of eating behavior and energy homeostasis [28–30]. In the brain, the ECS regulates food intake by modulating activity of the hypothalamus and the limbic system [31]. In the hypothalamus, endocannabinoids are released on demand after short-term food deprivation. Thereafter, the ECS transiently regulates food intake by enhancing orexigenic mediators such as ghrelin and inhibiting anorexigenic mediators, namely leptin and cholecystokinin [32–34]. Activation of CB₁ by hypothalamic administration of AEA stimulates appetite [35], whereas inhibition of CB receptors by SR141716A (rimonabant) suppresses appetite [36].

Central dysfunction in the CB receptors has also been identified in metabolic disease. CB₁ in the forebrain and in sympathetic neurons can regulate thermogenesis and energy balance [37]: conditional knockout mice lacking CB₁ in forebrain neurons result in mice with a lean phenotype that are resistant to diet-induced obesity. Furthermore, CB₁-deficient mice have increased energy expenditure [39]; and even following consumption of a high-fat diet (HFD) (49% of energy as fat) CB₁-deficient mice do not become obese [38].

Rimonabant, the most widely studied antagonist, has been shown to act as a CB₁ antagonist and inverse agonist [40,41]. Rimonabant was developed and marketed for the treatment of obesity but was withdrawn from the market in 2008 owing to severe psychological side effects. These are thought to have occurred as a result of the ability of rimonabant to cross the blood–brain barrier to target central CB₁, located in areas of the brain implicated in depression (prefrontal and frontal cortex, hippocampus, cerebellum) and anhedonia (nucleus accumbens, dorsal striatum). CB₁ antagonism (CB₁ knockout mice) also results in lower levels of several neurotransmitters, including serotonin, as reviewed in [42], which are thought to contribute to the adverse side effects observed. Thus, despite the adverse events with targeting the ECS centrally, the ability of this system to modulate food intake has led to more-recent research that has investigated peripheral modulation of CB₁ as an obesity therapeutic.

Peripheral modulation of CB₁ and CB₂

Much of our understanding about the role of the CB receptors in normal physiology has come from studies focused on their activity in disease states. Crucial to the development of therapeutics targeting the peripheral CB system is an understanding about the role they take in numerous organs and systems. Importantly, several research studies have demonstrated links between the disruption of the ECS and metabolic disease. Specifically, altered expression of CB₁ and CB₂ has been identified in several tissues from obese animals (for review, see [43]). Typically, CB₁ expression is increased in obesity in a tissue-specific manner, and CB₂ expression is decreased in obesity [44,45]. Moreover, diet-induced obesity increases AEA and 2-AG concentrations in the brain and peripheral tissues of mice [46]. In a human study, circulating 2-AG levels were significantly elevated in obese compared with lean individuals

and significantly correlated with body mass index (BMI), percent body fat and visceral fat in males and females [47]. In addition, plasma 2-AG but not AEA levels were positively correlated with cardio-metabolic risk factors, including intra-abdominal adiposity in obese men [48]. A recent study found that the circulating levels of 2-AG are higher in insulin-resistant compared with insulin-sensitive obese postmenopausal women [49]. Within the periphery, the ECS modulates the production of hormones from the gut and pancreas, and controls functions within the liver, adipose tissue, heart and skeletal muscle (Figure 2) – organs that are key to the progression of metabolic disease. Thus, several researchers have proposed that the development of peripherally restricted CB receptor antagonists could yield novel and exciting therapeutics in obesity [50,51].

Endocannabinoids and leptin signaling

The adipokine leptin plays a key part in food intake, bodyweight control and metabolism. The main role of leptin is via the modulation of neuronal signaling pathways in the hypothalamus where it acts as an anorexigenic mediator of food intake, acting via the leptin receptor Ob-Rb [52]. Because cannabinoids are orexigenic, hypothalamic concentrations of cannabinoids are inversely correlated with plasma concentrations of leptin [33]. Anorexigenic proopiomelanocortin (POMC) and orexigenic neuropeptide Y (NPY) expressing neurons in the arcuate nucleus (ARC) are potential targets for the action of leptin in the regulation of feeding behavior [53]. The peripheral CB₁ antagonist JD5037 has recently been demonstrated to restore hypothalamic leptin sensitivity by activating anorexigenic POMC neurons [54], with JD5037 also demonstrated to reduce obesity by reversing leptin resistance in diet-induced obese (DIO) mice [55]. Further research has demonstrated that leptin directly inhibits endocannabinoid synthesis by reducing intracellular calcium levels and glucocorticoid-

mediated CB release [56,57]. AEA is significantly reduced in white adipose tissues (WAT) following leptin infusion in rats [58]. In isolated human cytotrophoblasts, 2-AG downregulates leptin expression, which is reversed by CB₁ and CB₂ antagonists, suggesting that the 2-AG regulation of leptin expression is dependent on CB receptors [59].

Mitochondrial modulation by CB signaling

Metabolic disturbances such as diabetes and obesity are associated with altered mitochondrial respiratory function [60,61]. Importantly, endocannabinoids have been found to modulate mitochondrial morphology and membrane permeability [62]. AEA promotes mitochondrial swelling and membrane fluidity but downregulates cytochrome release and membrane potential [63,64]. In isolated rat liver mitochondria, AEA inhibits oxidative phosphorylation by blocking F₀/F₁ ATP synthase activity [65]. In addition, endocannabinoid, phytocannabinoid and synthetic CB receptor agonists such as AEA, Δ 9-THC and HU 210 reduce mitochondrial oxygen consumption in a dose-dependent manner in rat heart mitochondria [66]. This study further demonstrated that CB₁ agonists induce biphasic changes in complex I and/or complex II/III activities. In 2008, Tedesco *et al.* investigated the effects of CB₁ deletion or antagonism in W and isolated mature white adipocytes of HFD mice (60% kcal fat). They observed that CB₁ deletion or chronic rimonabant treatment countered HFD-dependent reductions in endothelial nitric oxide synthase (eNOS) expression and mitochondrial biogenesis, an effect linked to reduced adiposity and bodyweight [67]. In addition, CB₁ deletion or chronic rimonabant treatment on WAT and isolated mature white adipocytes of HFD mice countered HFD-dependent reductions in eNOS expression and mitochondrial biogenesis, an effect linked to reduced adiposity and bodyweight [68].

Recent research has demonstrated that CB₁ is localized to muscle mitochondria [69]. In the mitochondria, CB₁ activation with THC decreases mitochondria-coupled respiration, which was absent in CB₁ knockout mice [69]. Specifically, CB₁ is thought to be involved in the mitochondrial regulation of oxidative activity through enzymes responsible for the pyruvate metabolism pathway. CB₁ is also present in the membrane of mouse neuronal mitochondria (mtCB₁) which regulates brain mitochondrial activity and energy metabolism [70]. Recent studies have demonstrated that genetic deletion of hippocampal mtCB₁ prevents CB-induced reduction in memory formation, suggesting that mtCB₁ mediates memory processes through mitochondrial energy metabolism [71]. In addition, CB₁ in mitochondria of POMC cells regulates mitochondrial adaptations and CB-induced feeding in *Pomc-cre* mice [72].

ECS in the liver: lipid metabolism

Despite low expression, CB₁ is expressed in liver cells, including hepatic stellate cells (HSCs) [73,74] and hepatocytes [75]. CB₂ is undetectable in healthy liver tissue but is upregulated in pathological conditions such as non-alcoholic fatty liver disease (NAFLD) [76], hepatic fibrosis [77] and hepatocellular carcinoma (HCC) [78]. A recent human study demonstrated for the first time that serum levels of 2-AG, but not AEA, are significantly increased in patients with NAFLD, independent of obesity status of the patient [79].

Several studies have suggested that targeting the ECS in the liver could have benefits in obesity. In rodents consuming a HFD, there is an increase in CB₁ protein expression in purified liver plasma membranes. Further, agonism of CB₁ in mice consuming a standard chow diet elevates *de novo* lipogenesis via sterol regulatory element binding protein-1c (SREBP-1c), a lipogenic transcription factor regulating fatty acid synthase (FAS) and other lipogenic enzymes [80]. The mechanism for this is a reduction in fatty acid amide hydrolase (FAAH)

which is likely to be independent of the central modulation of the ECS. This study was supported by later work that confirmed a reduced rate of *de novo* lipogenesis in the liver of specific CB₁ knockout mice [81]. In a diet-induced obesity mouse model, CB₁ antagonism improves liver steatosis and lipid handling [82]; and in obese Zucker fa/fa rats CB₁ antagonism reverses liver steatosis and reduces steatohepatitis-associated high liver tumor necrosis factor (TNF)- α levels [83]. These findings have been supported by *in vitro* studies in hepatic cells, which demonstrate an improved lipogenesis after CB₁ antagonist treatment [84,85]. Reversal of HFD-induced hepatic steatosis and fibrosis by CB₁ antagonism is mediated by adiponectin via increasing fatty acid oxidation and reducing free fatty acid uptake into the liver [86]. Hepatic CB₁ is necessary for HFD-induced hepatic insulin resistance because hepatocyte-specific CB₁ knockout mice receiving HFD remain insulin sensitive [87]. Studies have also shown that hepatic insulin resistance induced by HFD in murine models is mediated by CB₁-dependent activation of the long-chain ceramide synthesis in liver [88]. These findings suggest hepatic CB₁ as a potential therapeutic target for obesity-associated insulin resistance.

In humans, CB₂ is increased in individuals with liver disease [76]. Several studies report that CB₂ agonists increase the extent of hepatic steatosis [89,90]. CB₂ agonist JWH133 enhanced HFD-induced hepatic steatosis in wild-type mice; however, the effect was blunted in CB₂-deficient mice [89]. An *in vitro* study demonstrated that CB₂-selective agonist AM1241 increases the degree of steatosis in oleic-acid-treated fatty hepatocytes [90]. Thus, targeting the ECS in the liver directly can modulate disease phenotype.

ECS in adipose tissue

Adipose tissue contributes to the regulation of many physiological processes, and dysfunction fundamentally underpins obesity and related co-morbidities [91]. Further, this endocrine

organ produces physiologically important proteins such as leptin, lipoprotein lipase and adiponectin [92]. Several studies suggest that endocannabinoids directly regulate lipid metabolism in adipose tissues *in vitro* [33,93]. Indeed, CB₁ is expressed in adipose tissue and elevated during adipogenesis [30,47,93]. CB₁ is expressed in epidymal adipose tissue and adipocytes and CB₁ agonists increase adipocyte lipoprotein lipase (LPL) activity dose-dependently in primary adipocyte cultures, whereas rimonabant reduces this effect [93]. Rimonabant also stimulates adiponectin expression in cultured adipocyte cells and reduces hyperinsulinemia in obese rats [44]. Interestingly, CB₁ expression and FAAH were elevated in mature human adipocytes compared with preadipocytes [94], suggesting an important yet undiscovered role for the ECS in functional adipocytes. Cable *et al.* reported a correlation between the endocannabinoid metabolizing enzyme FAAH and bodyweight in subcutaneous adipocytes in metabolically healthy humans. However, another catabolic enzyme: monoacylglycerol lipase (MAGL), does not correlate with bodyweight [95]. Thus, the relationship between bodyweight and the expression of components of the ECS in adipose tissue might not be straightforward. Furthermore, agonism of CB₁ enhances while rimonabant reduces insulin sensitivity in cultured adipocytes [96]. It is unlikely that this is via the modulation of glucose homeostasis because activation of endocannabinoids in human adipocytes promotes GLUT4 translocation and glucose uptake independently of insulin [97].

A recent study identified that peripheral antagonism of CB₁ in adipocytes enhances transdifferentiation of white adipocytes to the brown fat phenotype which would improve metabolism via enhancing thermogenesis [98]. In addition, chronic CB₁ antagonism activates brown adipose tissue (BAT) thermogenesis and enhances energy expenditure and glucose utilization in DIO mice [99].

ECS in the heart: role in cardiovascular disease

Obesity increases the risk of co-morbidities including cardiovascular disease, increasing the risk of developing ischemic heart disease [100]. Endocannabinoids have been studied in cardiac ischemia-reperfusion (I/R) injury. 2-AG and palmitoylethanolamide (PEA), but not AEA, protected the isolated rat heart against ischemia through agonism of CB₂ [101]. Other studies have supported the role for CB₂ but not CB₁ in myocardial I/R injury [102–105]. In isolated cardiomyocytes, treatment with rimonabant decreases transforming growth factor (TGF)- β 1 fibrosis [106], suggesting that CB₁ antagonism does have a direct benefit to the heart.

In addition to ischemic heart disease, the ECS has been shown to play a major part in atherosclerosis [107,108]. Low-dose CB therapy reduces the progression of atherosclerosis in mice, predominantly by inhibiting macrophage recruitment [107]. Increased levels of 2-AG were reported in aortas and visceral adipose tissue in the pro-atherosclerotic model of ApoE null mice fed a high cholesterol diet, although CB₂ antagonism did not affect plaque formation [108]. However, CB₁ antagonism with rimonabant reduced atherosclerosis development in the aortic sinus in low-density lipoprotein (LDL)-receptor-deficient mice through anti-inflammatory effects [109]. In addition, rimonabant improves endothelial dysfunction by decreasing reactive oxygen species (ROS) production in the vessel wall of ApoE null mice fed a cholesterol-rich diet, although atherosclerotic plaque formation was not reduced [110].

In contrast to effects of CB₁ activation, selective agonism of CB₂ reduces atherosclerosis. For instance, the selective CB₂R agonist JWH015 reduced monocyte migration by reducing chemokine receptor expression in human cultured myocytes, which is generally upregulated in inflammation-mediated atherosclerosis [111]. Similarly, the CB₂ agonist JWH133 decreased atherosclerotic lesion formation, improved endothelial function

and reduced ROS levels in high-cholesterol-fed ApoE null mice. Interestingly, ApoE and CB₂ double knockout mice developed inflammatory cell infiltration in atherosclerotic plaques compared with ApoE null mice, suggesting a protective role of CB₂ in atherosclerosis [112]. Furthermore, *in vitro* analysis has shown that CB₂ activation reduces TNF- α -induced proliferation and migration of human vascular smooth muscle cells [113]. More recently, Netherland-Van Dyke *et al.* investigated the effects of CB receptor agonists on the development of atherosclerosis in CB₂^{+/+} and CB₂^{-/-} LDL receptor null mice and observed that lesional apoptosis and macrophage accumulation is CB₂ dependent [114]. These data provide strong evidence regarding the opposing roles of CB₁ and CB₂ in cardiovascular disease, suggesting selective CB₂ activation and CB₁ antagonism as an attractive target for the treatment of atherosclerosis.

ECS in the skeletal muscle: insulin sensitivity

It is now well accepted that the components of the ECS are expressed in muscle cells [115]. Specifically, CB₁, CB₂ and FAAH are expressed in human and rodent skeletal muscle [116]. The first study to investigate the role of the ECS in skeletal muscle showed that the CB₁ antagonist rimonabant increases glucose uptake in isolated soleus muscle from Lep^{ob}/Lep^{ob} mice [117]. Further, in isolated cells AEA modulates skeletal muscle oxidative pathways [115]. However, not all the effects of AEA are sensitive to CB₁ antagonism, suggesting the presence of other CB receptors [115]. CB₁ expression is increased in the soleus muscle of HFD-fed mice [34], with Lindborg *et al.* reporting a decreased CB₁ expression in the soleus of insulin-resistant obese Zucker rats compared with lean controls [118]. Similarly, CB₂ expression is decreased and MAGL expression upregulated in skeletal muscle of HFD-fed rats [119]. A recent study suggested that dietary intake rather than the presence of obesity influenced ECS activity in

skeletal muscle, because a HFD was shown to downregulate muscle CB₁ and MAGL mRNA expression in normal and obese individuals, whether obesity was present or not [120]. Further, high n-3 PUFA intake increases expression of CB₁, CB₂ and EC synthesis enzymes in quadriceps muscles [121]. This suggests that the n-3 PUFA intake controlled the expression of the ECS.

Skeletal muscle accounts for ~70–90% of total glucose disposal under post-prandial conditions [122,123]. CB₁ plays an important part in the development of insulin resistance in skeletal muscle. AEA and adipocyte conditioned medium (CM) impairs insulin-stimulated Akt (ser473) phosphorylation in a CB₁-dependent manner in cultures of skeletal muscle cells [124]. Insulin-stimulated glucose transport is significantly increased in the isolated soleus muscle following the chronic treatment of rimonabant [125]. Mechanistically, Lipina *et al.* found that the mixed CB₁/CB₂ agonist WIN 55,212-2 downregulates insulin-stimulated ERK1/2 but not Akt activation in cultured skeletal muscle cells, whereas rimonabant sensitizes Akt and ERK1/2 signaling in myotubes, suggesting a role for the ECS in regulating muscle metabolism and function [126].

ECS in the gastrointestinal tract

The role of the ECS in the gastrointestinal tract is generally associated with feeding behavior [127–129]; however, it could also play an important part in regulating gut inflammation and thus permeability. Mechoulam *et al.* first provided evidence of the ECS in the gastrointestinal tract in 1995, detecting 2-AG but not AEA in canine gut [130]. Later, Izzo *et al.* demonstrated that AEA and 2-AG were present in the mouse small intestine [131]. CB₁ is present in normal colonic epithelium, smooth muscle and the submucosal myenteric plexus, CB₁ and CB₂ are

expressed on plasma cells in the lamina propria and CB₂ was present on gut-associated macrophages [132].

The main function of CBs in the gastrointestinal tract could be via the modulation of hormones that regulate hunger, with CB₁ and CB₂ co-localized with peptides regulating appetite in the gastrointestinal tract. Ghrelin, a circulating 28 amino acid peptide, is an orexigenic and adipogenic hormone [133]. During food deprivation, ghrelin levels increase while leptin levels decrease [133]. The orexigenic effects of ghrelin are mediated by AMP-activated protein kinase (AMPK) and are associated with central and peripheral metabolic effects [134]. Tucci *et al.* demonstrated that rimonabant can inhibit the orexigenic effect of ghrelin [135] and the same group reported no orexigenic effect of ghrelin in CB₁ knockout mice, providing strong evidence for CB₁ dependence of ghrelin effects on AMPK activity [32].

Recently, Alen *et al.* reported that peripheral CB₁ antagonism with LH-21 counteracted the orexigenic effects of ghrelin in rats [136]; however the exact mechanism remains unclear, although gastric CB₁ modulates ghrelin production through a mammalian target of rapamycin (mTOR) pathway [137]. Importantly, Kola *et al.* suggested that the metabolic effect of ghrelin on AMPK in peripheral tissues is abolished in the absence of functional CB₁, involving direct peripheral and central effects [138]. In addition, the gastrointestinal-secreted anorexigenic peptide hormone cholecystokinin (CCK) is also linked with the ECS, with CCK downregulating CB₁ expression [139]. Thus, endocannabinoids could mediate satiety signaling from the gastrointestinal tract.

ECS in the pancreas

CB₁ and CB₂ are both present in the islets of Langerhans, where CB₁ localizes predominantly to α cells and CB₂ is found in α cells and insulin-containing β cells [140,141]. *In vitro*

stimulation of CB₁ in β cells enhances basal and glucose-stimulated insulin secretion [141,142]; however, CB₂ agonism lowers glucose-dependent insulin secretion [141]. Rimonabant reportedly decreases basal insulin hypersecretion in isolated obese rat islets without affecting basal secretion in islets from lean rats [143]. By contrast, Li *et al.* reported that CB₁ and CB₂ antagonists fail to inhibit insulin secretion, suggesting involvement of CB-receptor-independent pathways in effects of some cannabinoids [144]. Kim *et al.* observed that CB₁ blockade enhanced insulin receptor signaling in β cells through the insulin receptor substrate 2-Akt pathway, and increased β cell proliferation and reduced blood glucose in *db/db* mice [145]. These contrasting results regarding the effects of CB receptor agonists and antagonists on insulin secretion warrant further studies. Recently, studies have reported that peripheral blockade of CB₁ reverses macrophage infiltration in Zucker diabetic fatty (ZDF) rats and selective knockdown of macrophage CB₁ mitigates T2DM, suggesting macrophage-expressed CB₁ as a potential target for the management of T2DM [146]. The same group later generated CB₁-deficient rats on ZDF background to observe whether there is an obligatory role of CB₁ in T2DM. They have identified that CB₁-deficient ZDF rats have improved β cell function and hyperglycemia [147].

ECS in renal function

Deutsch and Chin initially proposed the presence of the ECS in the renal system in 1993, reporting amidase activity in rat kidneys [148]. Studies confirm the presence of CB₁ throughout the nephron, including within the glomerulus [149,150], arterioles [151], tubules [152], loop of Henle [153], collecting ducts [154] and interstitium [152]. The ECS could play a part in normal tubular physiology because proximal tubule cells (PCT) express CB₁ and CB₂ [155].

It is well known that obesity is associated with developing end-stage renal disease [156,157]. Several studies have explored the role of ECS in obesity-linked kidney disease [158,159]. CB₁ is elevated in kidneys from obese rats [158], and CB₂ is downregulated in the kidneys of obese rats [160]. Further, CB₁ antagonism improves renal function, presumably by a reduction in bodyweight. Jenkin *et al.* found that chronic CB₁ antagonism improves albuminuria and renal tubular structure in diet-induced obese rats [158]. The effect of CBs in renal function could be mediated through specific renal cell types. The role of CB₁ in renal proximal tubular cells (RPTCs) in obesity-induced renal dysfunction in RPTC-specific CB₁ knockout (RPTC CB₁R^{-/-}) mice has been recently examined. This study found that RPTC CB₁R^{-/-} mice are protected from obesity-induced lipid accumulation in the kidney, kidney injury, renal inflammation and fibrosis through the liver kinase B1/AMP-activated protein kinase pathway, suggesting the specific role of RPTCs in CB₁-mediated nephropathy [159]. Furthermore, the CB₂ agonist AM1241 improves obesity-related renal dysfunction, whereas CB₂ antagonism reduces creatinine clearance and increases kidney weight leading to renal dysfunction in diet-induced obese rats [160]. Importantly, CB₂ agonism improves renal fibrosis and function, independent to any change in bodyweight [160]. Mechanistically, this could be via a reduction in circulating leptin concentrations, occurring in the absence of a reduction in bodyweight. Within the kidney, CB₂ expression is downregulated by high concentrations of albumin [161], suggesting that, under normal physiological conditions, CB₂ plays a part in protein handling by the kidney. Collectively, these studies provide strong evidence for the therapeutic potential of targeting CB₁ and CB₂ in the treatment of obesity-related renal diseases.

ECS and immunoinflammatory system dysregulation

The effects of the ECS in these different peripheral organ systems could involve modulation of the immune system and inflammation [57,162–164]. Obesity is characterized by chronic low-grade inflammation, an effect that reinforces the obesogenic phenotype (e.g., inducing insulin-resistance) and increases risk of obesity-related diseases including atherosclerosis and T2DM. These important inflammatory processes are responsive to the endocannabinoid system and CB antagonism.

The beneficial effects of CB₁ antagonism in obese patients are attributed in part to an increase of anti-inflammatory and metabo-regulatory adiponectin [165], together with adiponectin receptors [166] in peripheral tissues. Experimental studies confirm a CB₁-dependent stimulatory effect of endocannabinoids on adipose tissue adiponectin [44,167], whereas endocannabinoids act via CB₁ to suppress proinflammatory cytokines (MIP-1 β and IL-7) in association with upregulation of adiponectin in adipose tissue of obese subjects [168]. Beneficial effects of CB₁ antagonism on HFD-induced hepatic steatosis and fibrosis (but not improved adiposity and glycemic control) are adiponectin-receptor-dependent in mice [86]. Vascular dysfunction and atherosclerosis in obesity could also be responsive to anti-inflammatory actions of the ECS, with activation of CB₂ shown to limit TNF- α -induced human endothelial cell activation, adhesion and transendothelial migration of monocytes [169], and CB₁ and/or CB₂ is implicated in inhibiting endothelial inflammatory responses and TNF- α -dependent vascular smooth muscle cell proliferation and migration (important in atherosclerosis) [113,170].

Circulating endocannabinoid levels appear to be modulated in disease states associated with inflammation. Proinflammatory cytokines upregulate CB₁ and CB₂ expression in whole blood and mononuclear cells [171] and CB₁ in T lymphocytes [172,173]. CB₁ and CB₂ expression can be differentially regulated in association with altered cytokine levels in

inflammatory disease models [174,175]. Coupled with generally anti-inflammatory actions of the ECS, such observations support a regulatory feedback loop between inflammatory activation and the ECS. Indeed, endocannabinoids have been shown to suppress excess inflammation in experimental models of hepatic ischemia [176,177], LPS-dependent pulmonary inflammation [178], inflammatory pain [179,180], polymicrobial sepsis [181] and multiple sclerosis [182]. This feedback control of inflammatory cell recruitment and inflammatory mediator release by the ECS, which is potentially disrupted in disease, presents a potential therapeutic target.

Activation of CB₁ and CB₂ regulates cell migration and cytokine and chemokine production, with CB₂ activation by 2-AG inhibiting migratory activities of immune cells [183,184]. AEA also inhibits production of proinflammatory cytokines, so that it reduces human monocyte interleukin (IL)-6 and IL-8 [185]; and IL-2, TNF- α and interferon (IFN)- γ from activated human T lymphocytes [186]. In T cells, CB₂ activity can inhibit proliferation and release of IL-2, TNF- α , IL-17 and IFN- γ [186], and reduce differentiation and IL-17 release in T helper cells [187]. 2-AG also inhibits chemokine-induced chemotaxis of T cells [188]. In B cells, CB₂ activity promotes homing and retention to marginal zone in T-independent immune responses [189,190], modulates immunoglobulin class switching [191] and maintains germinal center B cells in T-dependent immunity [192]. In macrophages, CB₂ inhibits production of proinflammatory cytokines including IL-6, TNF- α and high mobility group box (HMGB)1 [193].

Despite evidence of anti-inflammatory effects of endocannabinoids, there is nevertheless evidence for proinflammatory effects in settings of doxorubicin-induced cardiomyopathy [194], nephropathy [194] and experimental dermatitis [195]. Endocannabinoids can also increase activated leukocyte function, and 2-AG could play a part

in leukocyte recruitment and inflammatory mediator release [196]. Interestingly, proinflammatory effects are more consistently linked to 2-AG rather than AEA, which, coupled with lack of effect of CB receptor agonists on leukocyte function in models of inflammation, suggests these stimulatory effects of endocannabinoids could be receptor independent and involve metabolite effects.

Development of peripheral specific CB ligands

Owing to the adverse effects of centrally targeted therapeutics, emerging research has focused on ligands that do not cross the blood–brain barrier. Several therapeutics have been developed that specifically antagonize CB₁ in the periphery. For example, the non-brain-penetrant neutral CB₁ antagonist AM6545 reduces food intake and bodyweight in rodents consuming a chow diet [197] and blocks hyperphagia in western-diet-induced obese mice [198]. AM6545 also improves leptin sensitivity and reduces adiposity in DIO mice [199]. It further reduces corticosterone-induced adiposity and attenuates the metabolic phenotype induced by corticosterone [200]. Furthermore, another compound: JD5037, a peripherally restricted CB₁ inverse agonist, decreases adipose tissue leptin secretion [55], which leads to a reversal of hypothalamic leptin resistance in diet-induced obese mice. JD5037 is also found to be effective in reducing bodyweight, hyperphagia and adiposity in an obese *Mage12*-null mouse model, an established experimental model for Prader–Willi syndrome (PWS), proposing a potential strategy for the management of obesity in PWS [201]. Finally, LH-21, a neutral CB₁ antagonist with poor brain penetration, has also been shown to reduce food intake [202], decrease leptin expression in visceral adipose tissue of diet-induced obese rats [68] and block the orexigenic effect of ghrelin [136]. Thus, research using several peripherally

acting CB₁ ligands suggests its central effects do not solely control the benefit of targeting this receptor in obesity.

Recent development in the area of CB therapeutics has led to the identification of drugs that can target CB₁ in the periphery as well as CB₂. Limited investigations have demonstrated the CB₁/CB₂ dual agonist CB-13 can inhibit cardiomyocyte hypertrophy via AMPK–eNOS signaling in isolated rodent neonatal cardiomyocytes [203]. In an additional study, a peripherally restricted CB₁/CB₂ dual agonist naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), in a whole mouse model of experimental colitis [204], inhibited colonic propulsion in CB₁ knockout mice, but not CB₂ knockout mice. Thus, these data suggest that targeting the ECS in the gastrointestinal tract is beneficial.

One significant limitation in these studies, in terms of the development of therapeutics for metabolic disease, is the observation that in obesity CB₁ is upregulated, whereas CB₂ is downregulated [158]. Therapeutics that act as dual agonists could therefore have mixed or limited efficacies. In this therapeutic area, a more relevant therapeutic would be to antagonize CB₁ and agonize CB₂. Recent investigations of the previously characterized CB₂ agonists: GW405833 [1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-3-[2-(4-morpholinyl)ethyl]-1H-indole] and AM1710 [1-hydroxy-9-methoxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one], demonstrate that they are indeed dual CB₂ agonists and CB₁ antagonists [205]. Although not yet investigated as an antiobesity therapeutic, AM1710 is not brain penetrant [206], which is suggestive of a potential therapeutic that warrants further investigation. Recently, a dual target peripheral CB₁ antagonist/iNOS inhibitor was reported to be effective in mitigating liver fibrosis, reducing bodyweight, hepatic steatosis and improving glucose tolerance in mice without inducing anxiety-like behavior [207,208]. A list of the emerging therapeutics is provided in Table 1.

Concluding remarks

Obesity and metabolic disease constitute a major health burden throughout the world. ECS dysfunction has been identified in several target organs where expression of the ECS is altered in metabolic disease. CB₁ is abundantly expressed in the brain, and globally targeting CB₁ leads to significant adverse outcomes. CB₂ is more abundant in the periphery, including the immune cells. Research using isolated cells in culture or tissues has demonstrated that modulation of the ECS in the periphery might be a potential therapeutic for metabolic disease. More-recent identification of peripheral specific CB ligands can reverse aspects of the metabolic phenotype. Further, dual CB ligands could be investigated as a potential therapeutic. Further work on the ECS is warranted for the targeting of metabolic disease.

Acknowledgments

We gratefully acknowledge the support of the Allen Foundation (USA) for our research in this area (D.H.H. and A.J.M.). Scholarship and fellowship funding is provided by Griffith University International Postgraduate Research Scholarship (GUIPRS-NS), the Griffith Health Top Up Scholarship (NS) and the Griffith University Postgraduate Research fellowship (GUPF-JSMC).

References

- 1 Di Marzo, V. *et al.* (2009) The endocannabinoid system as a link between homeostatic and hedonic pathways involved in energy balance regulation. *Int. J. Obes.* 33 (suppl. 2), 18–24
- 2 Pertwee, R.G. (2005) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. *AAPS J.* 7, E625–654
- 3 Pertwee, R.G. (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. *Addict. Biol.* 13, 147–159
- 4 Spigelman, I. (2010) Frontiers in neuroscience: therapeutic targeting of peripheral cannabinoid receptors in inflammatory and neuropathic pain states. In *Translational Pain Research: From Mouse to Man* (Kruger, L. and Light, A.R., eds), CRC Press/Taylor & Francis
- 5 Galiegue, S. *et al.* (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur. J. Biochem.* 232, 54–61
- 6 Gong, J.P. *et al.* (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. *Brain Res.* 1071, 10–23
- 7 Idris, A.I. and Ralston, S.H. (2012) Role of cannabinoids in the regulation of bone remodeling. *Front. Endocrinol.* 3, 136
- 8 Bab, I. *et al.* (2009) Cannabinoids and the skeleton: from marijuana to reversal of bone loss. *Ann. Med.* 41, 560–567
- 9 McHugh, D. *et al.* (2012) Delta(9)-tetrahydrocannabinol and *N*-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. *Br. J. Pharmacol.* 165, 2414–2424
- 10 Chu, Z.L. *et al.* (2010) *N*-Oleoyldopamine enhances glucose homeostasis through the activation of GPR119. *Mol. Endocrinol.* 24, 161–170
- 11 Martinez-Pinilla, E. *et al.* (2014) CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. *Exp. Neurol.* 261, 44–52
- 12 Kargl, J. *et al.* (2012) The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. *J. Biol. Chem.* 287, 44234–44248
- 13 Balenga, N.A. *et al.* (2014) Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling. *Br. J. Pharmacol.* 171, 5387–5406
- 14 De Petrocellis, L. *et al.* (2011) Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br. J. Pharmacol.* 163, 1479–1494
- 15 Hejazi, N. *et al.* (2006) Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. *Mol. Pharmacol.* 69, 991–997
- 16 Huffman, J.W. *et al.* (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. *J. Med. Chem.* 39, 3875–3877
- 17 Svizenska, I. *et al.* (2008) Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. *Pharmacol. Biochem. Behav.* 90, 501–511
- 18 Pertwee, R.G. (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *Br. J. Pharmacol.* 153, 199–215
- 19 Bloom, A.S. *et al.* (1997) Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. *Neurochemical Res.* 22, 563–568
- 20 Pertwee, R.G. (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. *Int. J. Obes.* 30 (suppl. 1), 13–18

- 21 Devane, W.A. *et al.* (1992) Isolation and structure of a brain constituent that binds to the
cannabinoid receptor. *Science* 258, 1946–1949
- 22 Sugiura, T. *et al.* (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor
ligand in brain. *Biochem. Biophys. Res. Commun.* 215, 89–97
- 23 Ibsen, M.S. *et al.* (2017) Cannabinoid CB1 and CB2 receptor signaling and bias. *Cannabis
Cannabinoid Res.* 2, 48–60
- 24 Laprairie, R.B. *et al.* (2016) Biased type 1 cannabinoid receptor signaling influences neuronal
viability in a cell culture model of Huntington disease. *Mol. Pharmacol.* 89, 364–375
- 25 Khajehali, E. *et al.* (2015) Biased agonism and biased allosteric modulation at the CB1
cannabinoid receptor. *Mol. Pharmacol.* 88, 368–379
- 26 Soethoudt, M. *et al.* (2017) Cannabinoid CB2 receptor ligand profiling reveals biased
signalling and off-target activity. *Nat. Commun.* 8, 13958
- 27 Dhopeswarkar, A. and Mackie, K. (2016) Functional selectivity of CB2 cannabinoid receptor
ligands at a canonical and noncanonical pathway. *J. Pharmacol. Exp. Ther.* 358, 342–351
- 28 Tibirica, E. (2010) The multiple functions of the endocannabinoid system: a focus on the
regulation of food intake. *Diabetol. Metab. Syndr.* 2, 5
- 29 Kim, J. *et al.* (2011) Endocannabinoid signaling and energy metabolism: a target for dietary
intervention. *Nutrition* 27, 624–632
- 30 Matias, I. and Di Marzo, V. (2007) Endocannabinoids and the control of energy balance.
Trends Endocrinol. Metab. 18, 27–37
- 31 Bermudez-Silva, F.J. *et al.* (2010) The endocannabinoid system, eating behavior and energy
homeostasis: the end or a new beginning? *Pharmacol. Biochem. Behav.* 95, 375–382
- 32 Kola, B. *et al.* (2008) The orexigenic effect of ghrelin is mediated through central activation
of the endogenous cannabinoid system. *PLoS One* 3, e1797
- 33 Di Marzo, V. *et al.* (2001) Leptin-regulated endocannabinoids are involved in maintaining
food intake. *Nature* 410, 822–825
- 34 Pagotto, U. *et al.* (2006) The emerging role of the endocannabinoid system in endocrine
regulation and energy balance. *Endocr. Rev.* 27, 73–100
- 35 Jamshidi, N. and Taylor, D.A. (2001) Anandamide administration into the ventromedial
hypothalamus stimulates appetite in rats. *Br. J. Pharmacol.* 134, 1151–1154
- 36 Colombo, G. *et al.* (1998) Appetite suppression and weight loss after the cannabinoid
antagonist SR 141716. *Life Sci.* 63, 113–117
- 37 Quarta, C. *et al.* (2010) CB(1) signaling in forebrain and sympathetic neurons is a key
determinant of endocannabinoid actions on energy balance. *Cell Metab.* 11, 273–285
- 38 Ravinet Trillou, C. *et al.* (2004) CB1 cannabinoid receptor knockout in mice leads to leanness,
resistance to diet-induced obesity and enhanced leptin sensitivity. *Int. J. Obes. Relat. Metab.
Disord.* 28, 640–648
- 39 Cota, D. *et al.* (2003) Endogenous cannabinoid system as a modulator of food intake. *Int. J.
Obes. Relat. Metab. Disord.* 27, 289–301
- 40 Lan, R. *et al.* (1999) Design and synthesis of the CB1 selective cannabinoid antagonist
AM281: a potential human SPECT ligand. *AAPS PharmSci* 1, 39–45
- 41 Landsman, R.S. *et al.* (1997) SR141716A is an inverse agonist at the human cannabinoid CB1
receptor. *Eur. J. Pharmacol.* 334, R1–2
- 42 Smaga, I. *et al.* (2014) The endocannabinoid/endovanilloid system and depression. *Curr.
Neuropharmacol.* 12, 462–474
- 43 Pagotto, U. *et al.* (2005) The endocannabinoid system and the treatment of obesity. *Ann.
Med.* 37, 270–275
- 44 Bensaid, M. *et al.* (2003) The cannabinoid CB1 receptor antagonist SR141716 increases
Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte
cells. *Mol. Pharmacol.* 63, 908–914

- 45 Pacher, P. and Mechoulam, R. (2011) Is lipid signaling through cannabinoid 2 receptors part
of a protective system? *Prog. Lipid Res.* 50, 193–211
- 46 Alvheim, A.R. *et al.* (2012) Dietary linoleic acid elevates endogenous 2-AG and anandamide
and induces obesity. *Obesity* 20, 1984–1994
- 47 Bluher, M. *et al.* (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid
system in human abdominal obesity. *Diabetes* 55, 3053–3060
- 48 Cote, M. *et al.* (2007) Circulating endocannabinoid levels, abdominal adiposity and related
cardiometabolic risk factors in obese men. *Int. J. Obes.* 31, 692–699
- 49 Abdulnour, J. *et al.* (2014) Circulating endocannabinoids in insulin sensitive vs. insulin
resistant obese postmenopausal women. A MONET group study. *Obesity* 22, 211–216
- 50 Van Gaal, L.F. *et al.* (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on
weight reduction and cardiovascular risk factors in overweight patients: 1-year experience
from the RIO-Europe study. *Lancet* 365, 1389–1397
- 51 Scherer, T. and Buettner, C. (2009) The dysregulation of the endocannabinoid system in
diabesity—a tricky problem. *J. Mol. Med.* 87, 663–668
- 52 Niki, M. *et al.* (2015) Modulation of sweet taste sensitivities by endogenous leptin and
endocannabinoids in mice. *J. Physiol.* 593, 2527–2545
- 53 Cheung, C.C. *et al.* (1997) Proopiomelanocortin neurons are direct targets for leptin in the
hypothalamus. *Endocrinology* 138, 4489–4492
- 54 Tam, J. *et al.* (2017) Peripheral cannabinoid-1 receptor blockade restores hypothalamic
leptin signaling. *Mol. Metab.* 6, 1113–1125
- 55 Tam, J. *et al.* (2012) Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by
reversing leptin resistance. *Cell Metab.* 16, 167–179
- 56 Jo, Y.H. *et al.* (2005) Integration of endocannabinoid and leptin signaling in an appetite-
related neural circuit. *Neuron* 48, 1055–1066
- 57 Malcher-Lopes, R. *et al.* (2006) Opposing crosstalk between leptin and glucocorticoids
rapidly modulates synaptic excitation via endocannabinoid release. *J. Neurosci.* 26, 6643–
6650
- 58 Buettner, C. *et al.* (2008) Leptin controls adipose tissue lipogenesis via central, STAT3-
independent mechanisms. *Nat. Med.* 14, 667–675
- 59 Costa, M.A. *et al.* (2015) 2-Arachidonoylglycerol impairs human cytotrophoblast cells
syncytialization: influence of endocannabinoid signalling in placental development. *Mol. Cell.*
Endocrinol. 399, 386–394
- 60 Lowell, B.B. and Shulman, G.I. (2005) Mitochondrial dysfunction and type 2 diabetes. *Science*
307, 384–387
- 61 Bhatti, J.S. *et al.* (2017) Mitochondrial dysfunction and oxidative stress in metabolic
disorders – a step towards mitochondria based therapeutic strategies. *Biochim. Biophys.*
Acta 1863, 1066–1077
- 62 Lipina, C. *et al.* (2014) Mitochondria: a possible nexus for the regulation of energy
homeostasis by the endocannabinoid system? *Am. J. Physiol. Endocrinol. Metab.* 307, E1–13
- 63 Catanzaro, G. *et al.* (2009) Anandamide increases swelling and reduces calcium sensitivity of
mitochondria. *Biochem. Biophys. Res. Commun.* 388, 439–442
- 64 Costa, M.A. *et al.* (2015) The endocannabinoid anandamide induces apoptosis in
cytotrophoblast cells: involvement of both mitochondrial and death receptor pathways.
Placenta 36, 69–76
- 65 Zaccagnino, P. *et al.* (2011) Anandamide inhibits oxidative phosphorylation in isolated liver
mitochondria. *FEBS Lett.* 585, 429–434
- 66 Athanasiou, A. *et al.* (2007) Cannabinoid receptor agonists are mitochondrial inhibitors: a
unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell
death. *Biochem. Biophys. Res. Commun.* 364, 131–137

- 67 Tedesco, L. *et al.* (2008) Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. *Diabetes* 57, 2028–2036
- 68 Alonso, M. *et al.* (2012) Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. *Br. J. Pharmacol.* 165, 2274–2291
- 69 Mendizabal-Zubiaga, J. *et al.* (2016) Cannabinoid CB1 receptors are localized in striated muscle mitochondria and regulate mitochondrial respiration. *Front. Physiol.* 7, 476
- 70 Benard, G. *et al.* (2012) Mitochondrial CB(1) receptors regulate neuronal energy metabolism. *Nat. Neurosci.* 15, 558–564
- 71 Hebert-Chatelain, E. *et al.* (2016) A cannabinoid link between mitochondria and memory. *Nature* 539, 555–559
- 72 Koch, M. *et al.* (2015) Hypothalamic POMC neurons promote cannabinoid-induced feeding. *Nature* 519, 45–50
- 73 Siegmund, S.V. *et al.* (2007) The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. *Faseb J.* 21, 2798–2806
- 74 Jeong, W.I. *et al.* (2008) Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. *Cell Metab.* 7, 227–235
- 75 Mukhopadhyay, B. *et al.* (2010) Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. *J. Biol. Chem.* 285, 19002–19011
- 76 Mendez-Sanchez, N. *et al.* (2007) Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. *Liver Int.* 27, 215–219
- 77 Julien, B. *et al.* (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. *Gastroenterology* 128, 742–755
- 78 Xu, X. *et al.* (2006) Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. *Cancer Genet. Cytogenet.* 171, 31–38
- 79 Zelber-Sagi, S. *et al.* (2017) Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. *Obesity* 25, 94–101
- 80 Osei-Hyiaman, D. *et al.* (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. *J. Clin. Invest.* 115, 1298–1305
- 81 Osei-Hyiaman, D. *et al.* (2008) Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. *J. Clin. Invest.* 118, 3160–3169
- 82 Jourdan, T. *et al.* (2010) CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. *Diabetes* 59, 926–934
- 83 Gary-Bobo, M. *et al.* (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. *Hepatology* 46, 122–129
- 84 Wu, H.M. *et al.* (2011) Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Galphai/o inhibition. *Mol. Pharmacol.* 80, 859–869
- 85 Shi, D. *et al.* (2014) Inhibiting CB1 receptors improves lipogenesis in an *in vitro* non-alcoholic fatty liver disease model. *Lipids Health Dis.* 13, 173
- 86 Tam, J. *et al.* (2014) Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. *Am. J. Physiol. Endocrinol. Metab.* 306, E457–468
- 87 Liu, J. *et al.* (2012) Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. *Gastroenterology* 142, 1218–1228

- 88 Cinar, R. *et al.* (2014) Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing *de novo* synthesis of long-chain ceramides. *Hepatology* 59, 143–153
- 89 Deveaux, V. *et al.* (2009) Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. *PLoS One* 4, e5844
- 90 De Gottardi, A. *et al.* (2010) Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes. *Liver Int.* 30, 1482–1489
- 91 Kusminski, C.M. *et al.* (2016) Targeting adipose tissue in the treatment of obesity-associated diabetes. *Nat. Rev. Drug Discov.* 15, 639–660
- 92 Guerre-Millo, M. (2002) Adipose tissue hormones. *J. Endocrinol. Invest.* 25, 855–861
- 93 Cota, D. *et al.* (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. *J. Clin. Invest.* 112, 423–431
- 94 Engeli, S. *et al.* (2005) Activation of the peripheral endocannabinoid system in human obesity. *Diabetes* 54, 2838–2843
- 95 Cable, J.C. *et al.* (2011) The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans. *Lipids Health Dis.* 10, 129
- 96 Motaghedi, R. and McGraw, T.E. (2008) The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. *Obesity* 16, 1727–1734
- 97 Pagano, C. *et al.* (2007) The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. *J. Clin. Endocrinol. Metab.* 92, 4810–4819
- 98 Perwitz, N. *et al.* (2010) Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. *Diabetes Obes. Metab.* 12, 158–166
- 99 Bajzer, M. *et al.* (2011) Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice. *Diabetologia* 54, 3121–3131
- 100 Varbo, A. *et al.* (2015) Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. *Circ. Res.* 116, 665–673
- 101 Lepicier, P. *et al.* (2003) Endocannabinoids protect the rat isolated heart against ischaemia. *Br. J. Pharmacol.* 139, 805–815
- 102 Di Filippo, C. *et al.* (2004) Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. *J. Leukoc. Biol.* 75, 453–459
- 103 Montecucco, F. *et al.* (2009) CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. *J. Mol. Cell. Cardiol.* 46, 612–620
- 104 Defer, N. *et al.* (2009) The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. *Faseb J.* 23, 2120–2130
- 105 Wang, P.F. *et al.* (2012) Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. *J. Cardiovasc. Pharmacol.* 59, 301–307
- 106 Slavic, S. *et al.* (2013) Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. *J. Mol. Med.* 91, 811–823
- 107 Steffens, S. *et al.* (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. *Nature* 434, 782–786
- 108 Montecucco, F. *et al.* (2009) Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. *Atherosclerosis* 205, 433–441
- 109 Dol-Gleizes, F. *et al.* (2009) Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. *Arterioscler. Thromb. Vasc. Biol.* 29, 12–18

- 110 Tiyerili, V. *et al.* (2010) CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. *Basic Res. Cardiol.* 105, 465–477
- 111 Montecucco, F. *et al.* (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. *Am. J. Physiol. Heart Circ. Physiol.* 294, H1145–1155
- 112 Hoyer, F.F. *et al.* (2011) Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells *in vivo*. *J. Mol. Cell. Cardiol.* 51, 1007–1014
- 113 Rajesh, M. *et al.* (2008) CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. *Br. J. Pharmacol.* 153, 347–357
- 114 Netherland-Van Dyke, C. *et al.* (2015) Cannabinoid receptor type 2 (CB2) dependent and independent effects of WIN55,212-2 on atherosclerosis in Ldlr-null mice. *J. Cardiol. Ther.* 3, 53–63
- 115 Cavuoto, P. *et al.* (2007) Effects of cannabinoid receptors on skeletal muscle oxidative pathways. *Mol. Cell. Endocrinol.* 267, 63–69
- 116 Cavuoto, P. *et al.* (2007) The expression of receptors for endocannabinoids in human and rodent skeletal muscle. *Biochem. Biophys. Res. Commun.* 364, 105–110
- 117 Liu, Y.L. *et al.* (2005) Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. *Int. J. Obes.* 29, 183–187
- 118 Lindborg, K.A. *et al.* (2010) Effects of *in vitro* antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. *Diabetes Obes. Metab.* 12, 722–730
- 119 Crespillo, A. *et al.* (2011) Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. *Biochem. J.* 433, 175–185
- 120 Engeli, S. *et al.* (2014) Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects. *Obesity* 22, E70–76
- 121 Hutchins-Wiese, H.L. *et al.* (2012) Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. *J. Nutr. Biochem.* 23, 986–993
- 122 Yki-Jarvinen, H. *et al.* (1987) Regulation of glycogen synthase and phosphorylase activities by glucose and insulin in human skeletal muscle. *J. Clin. Invest.* 80, 95–100
- 123 Eckardt, K. *et al.* (2011) Obesity-associated insulin resistance in skeletal muscle: role of lipid accumulation and physical inactivity. *Rev. Endocr. Metab. Disord.* 12, 163–172
- 124 Eckardt, K. *et al.* (2009) Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. *Diabetologia* 52, 664–674
- 125 Lindborg, K.A. *et al.* (2011) Effects of chronic antagonism of endocannabinoid-1 receptors on glucose tolerance and insulin action in skeletal muscles of lean and obese Zucker rats. *Cardiorenal. Med.* 1, 31–44
- 126 Lipina, C. *et al.* (2010) Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. *Diabetes* 59, 375–385
- 127 Di Carlo, G. and Izzo, A.A. (2003) Cannabinoids for gastrointestinal diseases: potential therapeutic applications. *Expert Opin. Investig. Drugs* 12, 39–49
- 128 McVey, D.C. *et al.* (2003) Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). *J. Pharmacol. Exp. Ther.* 304, 713–722
- 129 Massa, F. and Monory, K. (2006) Endocannabinoids and the gastrointestinal tract. *J. Endocrinol. Invest.* 29 (3 suppl.), 47–57
- 130 Mechoulam, R. *et al.* (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem. Pharmacol.* 50, 83–90

- 131 Izzo, A.A. *et al.* (2001) Cannabinoid CB1-receptor mediated regulation of gastrointestinal
motility in mice in a model of intestinal inflammation. *Br. J. Pharmacol.* 134, 563–570
- 132 Wright, K. *et al.* (2005) Differential expression of cannabinoid receptors in the human colon:
cannabinoids promote epithelial wound healing. *Gastroenterology* 129, 437–453
- 133 Tschop, M. *et al.* (2000) Ghrelin induces adiposity in rodents. *Nature* 407, 908–913
- 134 Kola, B. *et al.* (2005) Cannabinoids and ghrelin have both central and peripheral metabolic
and cardiac effects via AMP-activated protein kinase. *J. Biol. Chem.* 280, 25196–25201
- 135 Tucci, S.A. *et al.* (2004) The cannabinoid CB1 receptor antagonist SR141716 blocks the
orexigenic effects of intrahypothalamic ghrelin. *Br. J. Pharmacol.* 143, 520–523
- 136 Alen, F. *et al.* (2013) Ghrelin-induced orexigenic effect in rats depends on the metabolic
status and is counteracted by peripheral CB1 receptor antagonism. *PLoS One* 8, e60918
- 137 Senin, L.L. *et al.* (2013) The gastric CB1 receptor modulates ghrelin production through the
mTOR pathway to regulate food intake. *PLoS One* 8, e80339
- 138 Kola, B. *et al.* (2013) The CB1 receptor mediates the peripheral effects of ghrelin on AMPK
activity but not on growth hormone release. *Faseb J.* 27, 5112–5121
- 139 Burdyga, G. *et al.* (2004) Expression of cannabinoid CB1 receptors by vagal afferent neurons
is inhibited by cholecystokinin. *J. Neurosci.* 24, 2708–2715
- 140 Juan-Pico, P. *et al.* (2006) Cannabinoid receptors regulate Ca(2+) signals and insulin secretion
in pancreatic beta-cell. *Cell. Calcium* 39, 155–162
- 141 Bermudez-Silva, F.J. *et al.* (2008) Presence of functional cannabinoid receptors in human
endocrine pancreas. *Diabetologia* 51, 476–487
- 142 Matias, I. *et al.* (2006) Regulation, function, and dysregulation of endocannabinoids in
models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. *J. Clin.
Endocrinol. Metab.* 91, 3171–3180
- 143 Getty-Kaushik, L. *et al.* (2009) The CB1 antagonist rimonabant decreases insulin
hypersecretion in rat pancreatic islets. *Obesity* 17, 1856–1860
- 144 Li, C. *et al.* (2011) Cannabinoid receptor agonists and antagonists stimulate insulin secretion
from isolated human islets of Langerhans. *Diabetes Obes. Metab.* 13, 903–910
- 145 Kim, W. *et al.* (2011) Cannabinoids inhibit insulin receptor signaling in pancreatic beta-cells.
Diabetes 60, 1198–1209
- 146 Jourdan, T. *et al.* (2013) Activation of the Nlrp3 inflammasome in infiltrating macrophages by
endocannabinoids mediates beta cell loss in type 2 diabetes. *Nat. Med.* 19, 1132–1140
- 147 Jourdan, T. *et al.* (2017) Developmental role of macrophage cannabinoid-1 receptor
signaling in type 2 diabetes. *Diabetes* 66, 994–1007
- 148 Deutsch, D.G. and Chin, S.A. (1993) Enzymatic synthesis and degradation of anandamide, a
cannabinoid receptor agonist. *Biochem. Pharmacol.* 46, 791–796
- 149 Barutta, F. *et al.* (2010) Cannabinoid receptor 1 blockade ameliorates albuminuria in
experimental diabetic nephropathy. *Diabetes* 59, 1046–1054
- 150 Lin, C.L. *et al.* (2014) Cannabinoid receptor 1 disturbance of PPARgamma2 augments
hyperglycemia induction of mesangial inflammation and fibrosis in renal glomeruli. *J. Mol.
Med.* 92, 779–792
- 151 Koura, Y. *et al.* (2004) Anandamide decreases glomerular filtration rate through
predominant vasodilation of efferent arterioles in rat kidneys. *J. Am. Soc. Nephrol.* 15, 1488–
1494
- 152 Lecru, L. *et al.* (2015) Cannabinoid receptor 1 is a major mediator of renal fibrosis. *Kidney Int.*
88, 72–84
- 153 Silva, G.B. *et al.* (2013) Anandamide inhibits transport-related oxygen consumption in the
loop of Henle by activating CB1 receptors. *Am. J. Physiol. Renal Physiol.* 304, F376–381
- 154 Larrinaga, G. *et al.* (2010) Expression of cannabinoid receptors in human kidney. *Histol.
Histopathol.* 25, 1133–1138

- 155 Jenkin, K.A. *et al.* (2012) Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy. *Int. J. Biochem. Cell. Biol.* 44, 2028–2031
- 156 Ejerblad, E. *et al.* (2006) Obesity and risk for chronic renal failure. *J. Am. Soc. Nephrol.* 17, 1695–1702
- 157 Hsu, C.Y. *et al.* (2006) Body mass index and risk for end-stage renal disease. *Ann. Intern. Med.* 144, 21–28
- 158 Jenkin, K.A. *et al.* (2015) Chronic administration of AM251 improves albuminuria and renal tubular structure in obese rats. *J. Endocrinol.* 225, 113–124
- 159 Udi, S. *et al.* (2017) Proximal tubular cannabinoid-1 receptor regulates obesity-induced CKD. *J. Am. Soc. Nephrol.* 28, 3518–3532
- 160 Jenkin, K.A. *et al.* (2016) Renal effects of chronic pharmacological manipulation of CB2 receptors in rats with diet-induced obesity. *Br. J. Pharmacol.* 173, 1128–1142
- 161 Jenkin, K.A. *et al.* (2013) Cannabinoid receptor 2 expression in human proximal tubule cells is regulated by albumin independent of ERK1/2 signaling. *Cell Physiol. Biochem.* 32, 1309–1319
- 162 Tanasescu, R. and Constantinescu, C.S. (2010) Cannabinoids and the immune system: an overview. *Immunobiology* 215, 588–597
- 163 Turcotte, C. *et al.* (2015) Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. *J. Leukoc. Biol.* 97, 1049–1070
- 164 McCoy, K.L. (2016) Interaction between cannabinoid system and Toll-like receptors controls inflammation. *Mediators Inflamm.* 2016, 5831315
- 165 Despres, J.P. *et al.* (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. *N. Engl. J. Med.* 353, 2121–2134
- 166 Kabir, M. *et al.* (2015) CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors. *Am. J. Physiol. Endocrinol. Metab.* 309, E747–758
- 167 Murumalla, R. *et al.* (2011) Effect of the cannabinoid receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation. *J. Inflamm.* 8, 33
- 168 Ge, Q. *et al.* (2013) Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity. *Int. J. Obes.* 37, 874–880
- 169 Rajesh, M. *et al.* (2007) CB2-receptor stimulation attenuates TNF- α -induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. *Am. J. Physiol. Heart Circ. Physiol.* 293, H2210–2218
- 170 Wilhelmssen, K. *et al.* (2014) The endocannabinoid/endovanilloid *N*-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. *J. Biol. Chem.* 289, 13079–13100
- 171 Jean-Gilles, L. *et al.* (2015) Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells. *Acta Physiol.* 214, 63–74
- 172 Borner, C. *et al.* (2007) Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. *J. Leukoc. Biol.* 81, 336–343
- 173 Borner, C. *et al.* (2008) Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. *Mol. Pharmacol.* 73, 1013–1019
- 174 Lou, Z.Y. *et al.* (2011) Targeting CB(2) receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis. *Mol. Immunol.* 49, 453–461
- 175 Lou, Z.Y. *et al.* (2012) Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. *J. Neurosci. Res.* 90, 84–95
- 176 Batkai, S. *et al.* (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. *Faseb J.* 21, 1788–1800
- 177 Caraceni, P. *et al.* (2009) Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. *Gut* 58, 1135–1143

- 178 Berdyshev, E. *et al.* (1998) Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. *Life Sci* 63, 125–129
- 179 Comelli, F. *et al.* (2007) The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. *Br. J. Pharmacol.* 152, 787–794
- 180 Naidu, P.S. *et al.* (2010) Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. *J. Pharmacol. Exp. Ther.* 334, 182–190
- 181 Csoka, B. *et al.* (2009) CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. *PLoS One* 4, e6409
- 182 Mestre, L. *et al.* (2005) Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. *J. Neurochem.* 92, 1327–1339
- 183 Liu, Y.J. *et al.* (2013) Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway. *J. Biol. Chem.* 288, 13551–13562
- 184 Hasko, J. *et al.* (2014) CB2 receptor activation inhibits melanoma cell transmigration through the blood–brain barrier. *Int. J. Mol. Sci.* 15, 8063–8074
- 185 Berdyshev, E.V. *et al.* (1997) Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. *Eur. J. Pharmacol.* 330, 231–240
- 186 Cencioni, M.T. *et al.* (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. *PLoS One* 5, e8688
- 187 Guillot, A. *et al.* (2014) Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. *Hepatology* 59, 296–306
- 188 Coopman, K. *et al.* (2007) Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. *Int. Immunopharmacol.* 7, 360–371
- 189 Basu, S. *et al.* (2011) Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. *J. Immunol.* 187, 5720–5732
- 190 Muppidi, J.R. *et al.* (2011) Cannabinoid receptor 2 positions and retains marginal zone B cells within the splenic marginal zone. *J. Exp. Med.* 208, 1941–1948
- 191 Agudelo, M. *et al.* (2008) Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. *J. Neuroimmune Pharmacol.* 3, 35–42
- 192 Basu, S. *et al.* (2013) Cannabinoid receptor 2 (CB2) plays a role in the generation of germinal center and memory B cells, but not in the production of antigen-specific IgG and IgM, in response to T-dependent antigens. *PLoS One* 8, e67587
- 193 Gui, H. *et al.* (2013) Cannabinoid receptor 2 protects against acute experimental sepsis in mice. *Mediators Inflamm.* 2013, 741303
- 194 Mukhopadhyay, P. *et al.* (2010) CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. *Cardiovasc. Res.* 85, 773–784
- 195 Oka, S. *et al.* (2006) Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. *J. Immunol.* 177, 8796–8805
- 196 Gokoh, M. *et al.* (2005) 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. *Biochem. J.* 386, 583–589
- 197 Cluny, N.L. *et al.* (2010) A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. *Br. J. Pharmacol.* 161, 629–642

- 198 Argueta, D.A. and DiPatrizio, N.V. (2017) Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. *Physiol. Behav.* 171, 32–39
- 199 Tam, J. *et al.* (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. *J. Clin. Invest.* 120, 2953–2966
- 200 Bowles, N.P. *et al.* (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 112, 285–290
- 201 Knani, I. *et al.* (2016) Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome. *Mol. Metab.* 5, 1187–1199
- 202 Pavon, F.J. *et al.* (2006) Antiobesity effects of the novel *in vivo* neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. *Neuropharmacology* 51, 358–366
- 203 Lu, Y. *et al.* (2014) Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes. *J. Cardiovasc. Pharmacol.* 64, 420–430
- 204 Cluny, N.L. *et al.* (2010) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. *J. Pharmacol. Exp. Ther.* 334, 973–980
- 205 Dhopeswarkar, A. *et al.* (2017) Two Janus cannabinoids that are both CB2 agonists and CB1 antagonists. *J. Pharmacol. Exp. Ther.* 360, 300–311
- 206 Rahn, E.J. *et al.* (2011) Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabillactone class: antinociception without central nervous system side-effects. *Pharmacol. Biochem. Behav.* 98, 493–502
- 207 Cinar, R. *et al.* (2016) Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. *JCI Insight* 1, 11
- 208 Iyer, M.R. *et al.* (2017) Design, synthesis, and biological evaluation of novel, non-brain-penetrant, hybrid cannabinoid CB1R inverse agonist/inducible nitric oxide synthase (iNOS) inhibitors for the treatment of liver fibrosis. *J. Med. Chem.* 60, 1126–1141
- 209 Klumpers, L.E. *et al.* (2013) Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. *Br. J. Clin. Pharmacol.* 76, 846–857
- 210 Son, M.H. *et al.* (2010) Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. *Int. J. Obes.* 34, 547–556
- 211 Hsiao, W.C. *et al.* (2015) A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. *Diabetes Obes. Metab.* 17, 495–504
- 212 LoVerme, J. *et al.* (2009) Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. *Bioorg. Med. Chem. Lett.* 19, 639–643

Authors Biographies**Deanne Hryciw**

Deanne Hryciw is currently a senior lecturer in the Menzies Health Institute Queensland at Griffith University. She received her PhD in cellular physiology from University of South Australia. Her current research interests cover the endocannabinoid system, with a particular focus on altered peripheral systems in obesity. She is also interested in developmental programming, and the modulation of maternal dietary elements in programming offspring health. She has published over 50 peer-reviewed journal articles and referenced conference proceedings and book chapters. She has presented her research at national and international invited lectures on endocannabinoid signaling in obesity and leptin.



Nirajan Shrestha


Nirajan Shrestha is currently doing his PhD at Menzies Health Institute Queensland at Griffith University, Australia. He has done his MS in biomedical science from Chonbuk National University, South Korea and his BS in medical biochemistry from Pokhara University, Nepal. His current research focuses on the effect of maternal diet in offspring health. He is also interested in fatty acid metabolism, the endocannabinoid system and metabolic diseases. He has published three peer-reviewed journal articles and presented his research at different national and international conferences.

ACCEPTED MANUSCRIPT


Figure legends

Figure 1. Biosynthesis, degradation and metabolism of endocannabinoids. Abbreviations: AA, arachidonic acid; AEA, *N*-arachidonylethanolamine; 2-AG, 2-arachidonoylglycerol; NAPE-PLD, *N*-acyl phosphatidylethanolamine-specific phospholipase D; DAGL, diacylglycerol lipase; MAGL, monoacylglycerol lipase; AC, adenylyl cyclase; AMPK, 5' adenosine monophosphate-activated protein kinase; PKA, protein kinase A; NOS, nitric oxide synthase; FA, fatty acid.

Figure 2. Peripheral modulation of the endocannabinoid system (ECS). Abbreviations: FA, fatty acid; SREBP-1, sterol regulatory element-binding protein 1; LPL, lipoprotein lipase; GI tract, gastrointestinal tract.










ACCEPTED MANUSCRIPT






ACCEPTED MANUSCRIPT

Table 1. Novel therapeutic targets modulating ECS for the treatment of obesity and metabolic disease

SN	Compound	Chemical structure	Target	Effects	Refs
1	AM6545		Peripherally restricted CB ₁ neutral antagonist	Reduce food intake and bodyweight Improve dyslipidaemia by activating BAT ^a	[197]
2	TM38837		Peripherally selective CB ₁ inverse agonist	Predicated to improve metabolic profile (Currently in Phase I clinical trial)	[209]
3	JD5037		Peripherally selective CB ₁ inverse agonist	Attenuate glucose intolerance and insulin resistance Reverse leptin resistance	[199]
4	Compound-1		Peripheral CB ₁ selective antagonist	Reduce food intake and bodyweight Decrease hepatic SREBP-1c ^b	[210]
5	LH-21		Neutral CB ₁ antagonist (poor brain penetration)	Decrease food intake and bodyweight Reduce lipogenic enzymes	[202]

				Improve glucose handling	
6	BPR0912		Peripheral CB ₁ antagonist	Increase β -oxidation and thermogenesis in adipose tissue	[211]
Mixed CB₁ antagonist/CB₂ agonist					
1	URB447		Mixed CB ₁ antagonist/CB ₂ agonist	Reduce food intake and bodyweight gain in mice	[212]

2	GW405833		Mixed CB ₁ antagonist/CB ₂ agonist	Not known in obesity	[27]
3	AM1710		Mixed CB ₁ antagonist/CB ₂ agonist	Not known in obesity	[27]
Negative allosteric modulator					
1	Cannabidiol (CBD)		Noncompetitive negative allosteric modulator of CB ₁	Browning of 3T3-L1 adipocytes Inhibition of lipogenesis	[24]

^aBrown adipose tissue.

^bSterol regulatory-element-binding protein 1.

Accepted Manuscript

Title: Peripheral modulation of the endocannabinoid system in metabolic disease

Authors: Nirajan Shrestha, James S.M. Cuffe, Dana S. Hutchinson, John P. Headrick, Anthony V. Perkins, Andrew J. McAinch, Deanne H. Hryciw



PII: S1359-6446(17)30415-4
DOI: <https://doi.org/10.1016/j.drudis.2018.01.029>
Reference: DRUDIS 2162

To appear in:

Please cite this article as: Shrestha, Nirajan, Cuffe, James S.M., Hutchinson, Dana S., Headrick, John P., Perkins, Anthony V., McAinch, Andrew J., Hryciw, Deanne H., Peripheral modulation of the endocannabinoid system in metabolic disease. Drug Discovery Today <https://doi.org/10.1016/j.drudis.2018.01.029>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.